T4期前列腺癌的根治性局部治疗与局部控制改善及生存获益相关
回顾性分析1996-2020年单中心154例临床T4期前列腺癌患者,多数为腺癌(88%)、Gleason评分9-10分(77%)、中位基线PSA 20 ng/mL,54%为转移性cT4N0-1M1。局部治疗(放疗、手术或两者)与总生存改善(HR 0.3,P<0.001)及局部控制改善相关,多因素分析中局部治疗仍与生存改善相关(HR 0.58,P=0.02)。
要点
- cT4期前列腺癌异质性强,本组54%已有远处转移、24%区域淋巴结转移、22%局限于局部。
- 局部治疗与总生存改善相关(HR 0.3,P<0.001),多因素分析中仍相关(HR 0.58,P=0.02)。
- 局部治疗与局部复发 freedom 延长、局部进展减少、进展时梗阻症状减少及局部疾病死亡减少相关。
核心结论
- cT4期前列腺癌的根治性局部治疗与症状结局及生存改善相关,即使在转移性患者中亦然。
- 作者认为,在前瞻性评估之前,这些发现支持对选择性cT4病例行根治性局部治疗。
研究设计与样本
- 回顾性分析1996-2020年单中心治疗的154例临床T4期前列腺癌患者。
- 治疗为全身治疗联合或不联合局部治疗(手术、放疗或两者)。
- 采用Cox回归进行单因素和多因素分析,评估临床病理特征(包括梗阻症状)及接受局部治疗与总生存和疾病控制之间的关联。
主要发现
- 中位随访时间5.9年;大多数患者为腺癌(88%)、Gleason评分9-10分(77%),中位基线PSA为20 ng/mL。
- 54%为转移性cT4N0-1M1疾病,24%为区域进展期cT4N1M0,22%为局限性cT4N0M0。
- 局部治疗方式为放疗(n=44)、手术(n=28)或两者(n=9)。
- 局部治疗与总生存改善相关(HR 0.3,P<0.001),与无局部复发生存延长相关(HR 0.39,P=0.002),与局部进展减少相关(HR 0.41,P=0.02),与进展时梗阻症状减少相关(HR 0.31,P=0.01),与局部疾病死亡减少相关(HR 0.25,P=0.002)。
- 多因素分析中,局部治疗与生存改善相关(HR 0.58,P=0.02),转移性疾病(HR 2.93,P<0.001)或高危病理(HR 2.05,P=0.03)与生存更差相关。
临床怎么用
- 作者认为,在前瞻性评估之前,这些发现支持对选择性cT4期病例行根治性局部治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate patients with clinical (c)T4 prostate cancer (PCa), which represent both a heterogenous and understudied population, who often present with locally advanced disease and obstructive symptoms causing significant morbidity and mortality. We analysed whether receiving definitive local therapy influenced symptomatic and oncological outcomes. METHODS: Retrospective analysis of 154 patients with cT4 PCa treated at a single institution in 1996-2020. Systemic therapy with or without local treatment (surgery, radiotherapy [RT], or both). Uni- and multivariate analyses of associations between clinicopathological features (including obstructive symptoms) and receipt of local therapy on overall survival (OS) and disease control were done with Cox regression. RESULTS: The median follow-up time was 5.9 years. Most patients had adenocarcinoma (88%), Gleason score 9-10 (77%), and median baseline prostate-specific antigen (PSA) of 20 ng/mL; most (54%) had metastatic cT4N0-1M1 disease; 24% regionally advanced cT4N1M0, and 22% localised cT4N0M0. Local therapies were RT (n = 44), surgery (n = 28), or both (n = nine). Local therapy was associated with improved OS (hazard ratio [HR] 0.3, P < 0.001), longer freedom from local recurrence (HR 0.39, P = 0.002), less local progression (HR 0.41, P = 0.02), fewer obstructive symptoms with progression (HR 0.31, P = 0.01), and less death from local disease (HR 0.25, P = 0.002). On multivariate, local therapy was associated with improved survival (HR 0.58, P = 0.02), and metastatic disease (HR 2.93, P < 0.001) or high-risk pathology (HR 2.05, P = 0.03) was associated with worse survival. CONCLUSION: Definitive local therapy for cT4 PCa was associated with improved symptomatic outcomes and survival even among men with metastatic disease. Pending prospective evaluation, these findings support definitive treatment with local therapy for cT4 disease in select cases.
引用
- Andring LM, Abu-Gheida I, Bathala T, et al. Definitive local therapy for T4 prostate cancer associated with improved local control and survival. BJU Int. 2023. PMID: 37057728. doi:10.1111/bju.16027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。